Register Login
Register to leave comments
  • News bot Aug. 10, 2026, 8:21 p.m.

    📋 NKARTA, INC. (NKTX) - Financial Results

    Filing Date: 2026-08-10

    Accepted: 2026-08-10 16:12:21

    Event Type: Financial Results

    Event Details:

    NKARTA, INC. (NKTX) Reports the reporting period Financial Results NKARTA, INC. (NKTX) announced its financial results for the period ending the reporting period. Key Financial Highlights:
    • Revenue: Not disclosed
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 243178
      • targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B 2 cells as well as those implicated in autoimmune disease. Nkarta is evaluating NKX019 in multiple autoimmune conditions. About NkartaNkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for people living with autoimmune diseases. By harnessing the power of the innate immune system to eliminate pathogenic B cells driving the autoimmune response, Nkarta is advancing novel cell therapies engineered for deep therapeutic impact. The on-demand availability and outpatient dosing of our CAR-NK cells enables a broad population of patients with different autoimmune conditions to conveniently access NK cell therapy in community health settings. For more information, please visit the company’s website at www.nkartatx.com. Cautionary Note on Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995
      • planned for presentation at a medical conference in 2026

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2026 2025 Change ($) Change (%)
    Operating Expenses Loss From Operations 27.19K 74.00K $-46.82K -63.26%
    Other Income Net Interest Income 3.97K 5.38K $-1.41K -26.15%
    Other Income Net Other Income Net 239.00 428.00 $-189.00 -44.16%
    Other Income Net Net Loss 22.98K 68.20K $-45.22K -66.31%
    Other Income Net Net Loss Per Share 0.31 0.92 $-0.61 -66.30%
    Other Income Net Weighted Average Shares 73.98M 74.38M $-399.44K -0.54%
    Assets Property Equipment Net 56.77K 66.72K $-9.95K -14.92%
    Assets Operating Lease Right Of Use Assets 30.94K 34.43K $-3.49K -10.13%
    Assets Other Assets 6.76K 7.93K $-1.17K -14.79%
    Liabilities And Stockholders Equity Operating Lease Liabilities 73.54K 76.42K $-2.88K -3.77%
    Loss from Operations 43.13K 27.19K $15.94K +58.64%
    Interest Income 2.54K 3.97K $-1.43K -36.07%
    Other Income, Net 222.00 239.00 $-17.00 -7.11%
    Net Loss 40.37K 22.98K $17.39K +75.69%
    Property and Equipment, Net 56.77K 66.72K $-9.95K -14.92%
    Other Assets 6.76K 7.93K $-1.17K -14.79%
    Accounts Payable 16.37K 15.46K $904.00 +5.85%
    Operating Lease Liabilities 73.54K 76.42K $-2.88K -3.77%

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: NKARTA, INC.
    • Ticker Symbol: NKTX

Search

News categories